secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-142014
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology Q1 net loss $58.1M; cash $503.5M; zipalertinib dose change
----------------------------------------------------------------------------

- Net loss $58.1M for Q1 2023 vs $27.1M in Q4 2022; R&D expenses $52.1M including $25M upfront for CLN-418 license.
- Cash, equivalents, investments $503.5M as of March 31, 2023; runway into 2026.
- Zipalertinib pivotal study now enrolling at 100mg BID only; 150mg BID cohort discontinued per safety review.
- First clinical data for CLN-049 (EHA) and CLN-619 (ASCO) to be presented mid-2023.
- Licensed CLN-418 from Harbour Biomed for $25M upfront plus up to $563M in milestones and royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/0001193125-23-142014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523142014/d470233d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-142014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer